Head-to-head · WeighScore
Belle Health vs HealthRX
The verdict
HealthRX takes it — 86.1/100 to 77/100.
HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A LegitScript-certified (#50087439) physician-supervised program that runs a rare oral GLP tablet alongside the usual injectables — compounded semaglutide from ~$189/mo, tirzepatide/GLP+GIP up to ~$349, with a brand Ozempic pass-through if you need it.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Belle Health | HealthRX |
|---|---|---|
| WeighScore | 77/100 | 86.1/100 |
| Grade | C+ | B |
| Scorecard rank | #48 | #8 |
| Semaglutide | $119/mo | $189/mo |
| Tirzepatide | $199/mo (all doses, 3-month plan, compounded) | $349/mo |
| Coverage | All 50 states | Not publicly listed |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #48 · C+
Strengths
- Five named compounding pharmacy partners disclosed (Striker, Strive, OptioRx, Enovex, Braun PharmaCare)
- Flat-rate pricing — $119/mo semaglutide, $199/mo tirzepatide — doesn't rise at higher doses
- Free weekly registered-dietitian sessions included
- Operating since 2017
- LegitScript Certified
Where it loses points
- $199 tirzepatide price requires a 3-month bundle commitment
- Compounded medications are not FDA-approved
- Multi-pharmacy model — formulations may differ across orders
- FDA issued this company a warning letter dated 20 February 2026; the letter is public in FDA's warning-letter database
Graded #8 · B
Strengths
- LegitScript-certified (#50087439) — a genuine, verifiable trust signal
- Physician-supervised intake with licensed providers
- Both molecules plus a rare oral GLP tablet option
- Transparent flat monthly pricing, no insurance required
Where it loses points
- Compounded semaglutide/tirzepatide is not FDA-approved
- Some tiers are company-stated and the public site is thin
- Brand Ozempic is a steep pass-through (~$1,299)
- State count is not publicly listed
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.